Taking Exception to Phil Galwitz, CGMs

April 16, 2021 Updated: April 16, 2021

Editor’s Note: This letter is in response to the article “Glucose Monitors: Big Money, Little Evidence,” published in the Mind & Body section on March 24.

I’m a Type 2 diabetic. I now use the OmniPod insulin pump after years of trying medicines and diets that didn’t work.  I use a FreeStyle Libre 2 system for glucose monitoring to work efficiently with my pump. But no matter what I do to deal with the spiking sugars, the life-saving function in the sensor is a built-in alarm to wake me up at 3 a.m. when blood sugar decides to crash at 40 for no known reason.

I love The Epoch Times and know it can be influential because I am a journalist and see your values on information that is “fit to print.” It rarely exists anyplace else these days. But keep in mind, Abbott Labs has a product that is indispensable, and you should not be this ready to dismiss its cost/value for sake of cost. I live because of the meter.

I didn’t want diabetes; I suffered very high temperatures when I had German measles at age 12, which damaged my endocrine system. I think you need a counterpoint feature to take on Phil Galewitz’s opinion—even if he is established. He has been inconsiderate. Offer Abbott leaders a chance to share their views.

Thank you!

Brenda Bush